I think the point my ‘acquaintance’ was trying to make is that the European and Japanese markets are the two regions that we are most likely to make significant money from.
Not saying that other markets won’t get licensed but look to these deals in particular for revenue forecasting.
It would be interesting to know how other rare disease orphan medications are priced globally and what percentage different regions generate in terms of income
Share Price, page-4951
-
- There are more pages in this discussion • 6,718 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.61 |
Change
-0.180(1.31%) |
Mkt cap ! $1.762B | |||
| Open | High | Low | Value | Volume |
| $13.66 | $13.75 | $13.46 | $1.604M | 117.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 365 | $13.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.63 | 372 | 7 |
View Market Depth
| Last trade - 10.34am 05/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |